CAMK4 as a critical mediator of inflammation resolution and trained immunity
Active Project Grant Awarded Last action
- Award ID
- F31HL172670
- Recipient
-
Vanderbilt University UEI GTNBNWXJ12D5
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $135,184
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date 78% complete
- Place of performance
- Nashville, TN 37203, USA
Award details come from USAspending.gov.
Description
- Abstract
- Atherosclerotic cardiovascular disease (CVD) is the leading cause of death globally. Despite conventional lipid- lowering therapies to treat CVD, nearly 50% of patients suffer recurrent cardiac events that is attributed to excessive inflammation. Recent work from our group and others has demonstrated that failed resolution of a chronic inflammatory response is an important driver of inflammation seen in atherosclerotic plaques that result in clinical events. The resolution program is orchestrated by the efficient clearance of apoptotic cells (ACS) and the production of anti-inflammatory agonists known as specialized pro-resolving lipid mediators (spms). Notably, continual efferocytosis, which entails the successive uptake of ACS by individual macrophages in settings where cell death is rampant, is necessary to resolve inflammation. Advanced atherosclerotic plaques are characterized by large necrotic cores, caused by inefficient efferocytosis, and an imbalance of pro-inflammatory to pro- resolving mediators compared to early lesions, suggestive of failed resolution. Our primary aim for project is to uncover the endogenous cues that underlie dysregulated inflammation resolution seen in atherosclerosis. Intriguingly, recent publications suggest macrophages can have a memory-like response called "trained innate immunity". In response to an inflammatory stimulus such as oxidized low density lipoproteins (oxldl), innate immune cells undergo metabolic and epigenetic reprogramming that primes them to a 'hyperactive' state, where they can more rapidly mount an augmented secondary response. Hyper-responsiveness upon activation by a second innate stimuli ultimately boosts bacterial and viral immunity but may be detrimental for chronic diseases like atherosclerosis. Our preliminary data identified CA2+/calmodulin-dependent protein kinase IV (CAMK4) as regulator of both resolution and innate immune memory. Our preliminary data suggests that CAMK4 supports the proinflammatory phenotypes seen in innate immune memory in part due to its negative regulation on efferocytosis. Based on these findings, we hypothesize that myeloid CAMK4 is a critical mediator of immune memory and that immune training impairs resolution through a CAMK4-dependent mechanism. Aim 1 will test the hypothesis that trained immunity impairs continual efferocytosis in myeloid cells, promoting atheroprogression. Aim 2 will explore the role of CAMK4 in the development of trained immunity through its negative regulation of important resolution genes.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $34,859 | |
| Amendment | $1,280 | |
| Amendment | $33,015 | |
| Amendment | $0 | |
| Amendment | $33,015 | |
| Amendment | $0 | |
| Original award | $33,015 |
Quick answers
Who received award F31HL172670?
F31HL172670 was awarded to Vanderbilt University by National Heart Lung and Blood Institute (National Institutes of Health) on June 29, 2024.
How much is award F31HL172670 worth?
$135,184 has been obligated on F31HL172670.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award